ASX Announcement **27 January 2023**

Atomo Investor Webinar Presentation

Atomo Diagnostics Limited (ASX:AT1) (**Atomo**) is pleased to announce its participation in the Coffee Microcaps Morning Meeting to be held on **Monday 30th January 2023 from 9am AEDT**.

Chief Executive Officer John Kelly and Chief Financial Officer Will Souter will discuss key highlights from the December Quarter, and provide an overview of the Company which is a global leader in the user-centred design of innovative, accurate and reliable rapid diagnostics

This webinar can be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/WN_eUbhxnKoSx2xEiVPv9ThcQ

A recorded copy of the webinar will be made available following the event.

For more information, please contact:

John Kelly
Managing Director & CEO, Atomo
john.kelly@atomodiagnostics.com
+61 401 922 279

Investor Queries
investorqueries@atomodiagnostics.com

This announcement was authorised by the Chief Executive Officer

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com